Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, if he will make an assessment of the potential merits of providing additional funding to expedite approval for BAY1895344 to be available for cancer patients through the NHS.

Once a medicine is licensed in the United Kingdom, the National Institute for Health and Care Excellence (NICE) is the independent body responsible for developing authoritative, evidence-based recommendations for the National Health Service on whether new medicines represent an effective use of resources. The NHS in England is legally required to fund medicines recommended through a NICE appraisal, usually within three months of final guidance.

The Medicines and Healthcare products Regulatory Agency (MHRA) is responsible for ensuring new medicines are assessed for quality, safety and efficacy before being licensed and made available for patients. The MHRA is also responsible for regulation of clinical trials in the UK. Authorisation to conduct a Phase I/II trial of BAY 1895344 been granted by the MHRA.